{"id":"304072b052ef","type":"article","url":"https://hartvaat.nl/2025/12/16/geoxideerde-fosfolipiden-lp-a-en-cv-uitkomsten-na-acs/","title":"Geoxideerde fosfolipiden, Lp(a) en CV-uitkomsten na ACS","title_en":"Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["lipide-aferese"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.125.073855","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.125.073855","authors":["Sotirios Tsimikas","Michael Szarek","Christa M Cobbaert","Fred Romijn","J Wouter Jukema","Deepak L Bhatt","Vera A Bittner","Rafael Diaz","Sergio Fazio","Genevieve Garon","Chong Yuan","Xiao-Min Gong","Shaun G Goodman","Harvey D White","Joseph L Witztum","P Gabriel Steg","Gregory G Schwartz"],"significance":6,"published":"2025-12-16","source_date":"2025-12-16","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This analysis showed that oxidized phospholipids on apolipoprotein B and Lp(a) are synergistic risk factors for cardiovascular events after ACS, supporting combined measurement for comprehensive residual risk assessment.","created":"2026-07-03T10:32:05Z","updated":"2026-07-03T13:31:03Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse onderzocht de relatie tussen geoxideerde fosfolipiden, Lp(a) en CV-uitkomsten na ACS. OxPL en Lp(a) zijn synergistische risicofactoren die gerichte therapie vereisen.","abstract_original":"BACKGROUND: Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome in recent the era is not known. METHODS: OxPL-apoB levels and Lp(a) were measured in 11 630 participants before and 5185 participants 4 months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. Proportional hazards models adjusted for baseline covariates evaluated associations between log2-transformed OxPL-apoB and Lp(a) with MACEs. Interactions between the 2 biomarkers and treatment were also evaluated. RESULTS: Participants were followed for a median 2.9 years; the median age was 58 years, and 23.9% were female. Alirocumab reduced median placebo-adjusted OxPL-apoB by 13.0% and Lp(a) by 26.2% (both P<0.0001). In the placebo group, a doubling of baseline OxPL-apoB was associated with a hazard ratio (HR) of 1.081 (95% CI, 1.026-1.139; P=0.0034) for MACEs. Addition of Lp(a) to the model relegated the relationship of OxPL-apoB insignificant. In the alirocumab group, neither OxPL-apoB nor Lp(a) remained significantly associated with MACEs. A significant 3-way interaction was present among continuous log2 OxPL-apoB, Lp(a) stratified at the median, and treatment group on MACEs (Pinteraction=0.0023) so that, in the placebo group, increasing OxPL-apoB was associated with higher risk of MACEs when Lp(a) was below the median concentration but not above. In the alirocumab group, OxPL-apoB was not related to MACE risk irrespective of Lp(a) concentration. CONCLUSIONS: In patients with recent acute coronary syndrome receiving optimized statin treatment, elevated OxPL-apoB levels predicted MACEs, a relationship abrogated by alirocumab. The interaction of OxPL-apoB and Lp(a) in the placebo group indicates that OxPL-apoB independently predicts MACEs when Lp(a) levels are relatively low. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT001747 and NCT01663402."}